Table 2.
Clinical manifestations of SLE patients with CVST.
| Number | Gender/age (y) | Organ involvement | SLEDAI | Site of CVST occlusion |
Treatment | Outcome |
|---|---|---|---|---|---|---|
| 1 | F/16 | F, K, H | 21 | SSS, (B) TS, (B) SS | GC (pulse) + CTX | Lost |
| 2 | F/18 | F, K, H, C | 25 | (L) TS | GC (pulse) + CTX | Died |
| 3 | F/17 | F, R, A, K | 22 | (R) TS, (R) SS | GC + CTX | Died |
| 4 | F/20 | F, H | 15 | SSS | GC (pulse) + CTX | Survived |
| 5 | M/38 | H, K | 20 | SSS, (B) TS, (B) SS | GC (pulse) + CTX + FK506 | Survived |
| 6 | F/36 | R, A, H, C, P | 17 | (L) TS, (L) SS | GC + CTX | Survived |
| 7 | F/43 | R, A, S | 18 | SSS, (L) TS | GC + CTX | Survived |
| 8 | F/52 | A, K, S | 19 | (R) ISS, (L) TS | GC (pulse) + CTX | Survived |
| 9 | F/30 | F, K, P | 24 | (R) SS, (R) TS | GC (pulse) + CTX | Survived |
| 10 | F/20 | S, K, H, TTP | 30 | SSS, (L) TS | GC (pulse) + CTX + MMF + plasmapheresis | Survived |
| 11 | M/30 | None | 16 | SSS, (B) TS | GC (pulse) + CTX | Survived |
| 12 | M/14 | F, GI, K | 20 | (R) SS | GC (pulse) + CTX | Survived |
| 13 | F/41 | R, A, K | 18 | (B) TS, (B) SS | GC (pulse) + CTX | Died |
| 14 | M/28 | K, A | 20 | (L) SS, (L) TS | GC (pulse) + CTX | Survived |
| 15 | F/30 | R, H | 17 | (R) TS | GC + CTX | Survived |
| 16 | M/34 | K | 20 | (L) SS | GC (pulse) + CTX | Survived |
| 17 | F/15 | K, CAPS | 19 | SSS | GC (pulse) + CTX | Survived |
Organ Involvement. F: fever, R: rash, H: hemocytopenia, C: cardiac involvement, K: kidney disease, A: arthritis, P: pulmonary involvement, S: serositis, GI: gastrointestinal involvement, and CAPS: catastrophic antiphospholipid syndrome.
Site of CVST Occlusion. B: bilateral, L: left, R: right, SSS: superior sagittal sinus, ISS: inferior sagittal sinus, SS: sigmoid sinus, and TS: transverse sinus.
Treatment. GC: glucocorticoid, CTX: cyclophosphamide, and MMF: mycophenolate mofetil.